A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)

• Status: Recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kodiak Sciences Inc

Criteria

Inclusion Criteria:

• Signed informed consent prior to participation in the study.

• Type 1 or 2 diabetes mellitus

• Moderately severe to severe NPDR in the Study Eye (DRSS levels 47 and 53 as determined by the reading center), in which pan-retinal photocoagulation (PRP) can be safely deferred for at least 6 months per the Investigator.

• BCVA ETDRS letter score in the Study Eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)

• HbA1c of ≤12%.

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Presence of center-involved DME in the Study Eye

• Prior PRP in the Study Eye.

• Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment in the Study Eye.

• Prior intravitreal anti-VEGF treatment in the Study Eye for DR or DME.

• Prior intravitreal or periocular steroid in the Study Eye for DR or DME.

• Prior use of an investigational intravitreal treatment for DR or DME in the Study Eye.

• Any history or evidence of a concurrent ocular condition present in the Study Eye, that in the opinion of the Investigator could require either medical or surgical intervention or alter visual acuity during the study

• Active or suspected ocular or periocular infection or inflammation.

• Women who are pregnant or lactating or intending to become pregnant during the study.

• History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.

• Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event.

• Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value ≥ 100 mmHg while at rest.

• Other protocol-specified exclusion criteria may apply.